Developer docs
API playgroundTry for free, no card

Search company profiles

Vara

Full company profile

uuid0000jb3

Namestring
Vara
Legal namestring
MX Healthcare GmbH
Websiteurl
vara.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Vara (legal entity MX Healthcare GmbH) is a Berlin-based, venture-backed health AI company founded in 2018 that builds clinically validated, CE-marked (Class IIb under EU MDR) artificial intelligence for breast cancer screening. Its core product is an independent second reader for both screening and diagnostic mammography (2D and 3D tomosynthesis), built on a "decision referral" architecture that combines automatic normal triage, a Safety Net for potentially missed findings, and unclassified case handling that defers to radiologist judgment. The platform is offered as a SaaS/enterprise subscription delivered either as a PACS-integrated Vara Plugin or as the web-based Vara Workflow platform for screening programmes, with continuous performance monitoring and quarterly clinical review tied to cancer registry outcomes.

Vara generates revenue through annual, quote-based B2B enterprise subscriptions sold to national screening programmes, hospital radiology departments, and radiology groups. Go-to-market is a hybrid direct enterprise field sales motion (used to land large screening programmes such as Germany's national mammography screening programme, where Vara supports 50–60% of organised screening) combined with distribution partnerships (DeepC, Sectra Amplifier, Quibim, Medical Horizons) that resell the platform across more than 10 European countries. Customer segments are healthcare-provider led — radiologists, screening programmes, policymakers/health authorities, and hospital IT — with regulatory validation, peer-reviewed clinical evidence, and seamless PACS integration positioned as the primary purchase drivers.

The company has built its commercial position around the PRAIM study (approximately 460,000 women, published in Nature Medicine), which underpins regulatory approvals and marketing claims including a 17.6% improvement in cancer detection rate, up to 80% of normal cases pre-reported, an 84% workload reduction in programme-level configuration, and a Safety Net that detected 20.5% of cancers missed by radiologists. Leadership is co-founder led (Jonas Muff, CEO; Stefan Bunk, CTO) with functional depth across regulatory, product, software, sales, partnerships, and finance, and the company is headquartered at the Merantix AI Campus in Berlin.

Short descriptiontext

Vara is a Berlin-based health AI company that builds CE-marked (Class IIb) independent second-reader software for breast cancer screening, selling enterprise subscriptions to radiologists, hospitals, and national screening programmes across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI mammography screening, breast cancer detection, radiology workflow software, medical imaging AI, clinical decision support
Industry5 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAK
Teleradiology Platforms & Reading Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Software Publishers513210
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI / Radiology AI Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS/Software Subscription
TypeSubscription Recurring
Description

Cloud-based AI analysis platform deployed via PACS integration or Vara platform. Revenue generated through subscription/licensing model to healthcare systems, screening programmes, and hospitals.

vara.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise subscription for healthcare systems and screening programmes
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing not publicly disclosed

vara.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Vara develops and sells a CE-marked Class IIb AI software platform that analyses 2D mammograms and 3D digital breast tomosynthesis images to assist radiologists in breast cancer screening. The platform operates as an independent second reader, combining normal-case triage, a Safety Net that flags potentially missed findings, and automated reporting, and is delivered either as a PACS-integrated plugin or as a web-based workflow platform to hospitals and national/regional screening programmes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Cancer detection rate improved by 17.6% (6.7 vs 5.7 per 1,000)
+7 more records
Product overview1 text field

Vara offers a unified AI platform for breast cancer screening consisting of the core Vera AI engine and multiple integrated modules. The core Vera AI provides independent second reading capability (CE-marked Class IIb) for both screening and diagnostic mammography. Two deployment options exist: Vera Workflow (web-based platform with AI-driven prioritization, safety net alerts, normal triage, and automated reporting) and Vera Plugin (lightweight PACS-integrated solution with fast image analysis). The product portfolio has expanded from 2D mammography to include Vera Tomosynthesis (DBT) for 3D imaging, with the same CE-marked report and PACS integration. Continuous monitoring services ensure ongoing clinical safety through real-time performance tracking and quarterly review sessions.

Product and service5 records
1Vara AI (Mammography)
CategoryMedical Imaging AI
Description

CE-marked Class IIb AI platform that analyses 2D mammography images and serves as an independent second reader for both screening and diagnostic mammography, combining normal-case triage, Safety Net alerts, and automated reporting. Sold to hospitals, radiology groups, and national/regional screening programmes.

2Vara Tomosynthesis (DBT)
CategoryMedical Imaging AI
Description

AI for 3D digital breast tomosynthesis that analyses synthetic 2D, slabs, and complete 3D stacks and delivers the same CE-marked report and PACS integration as the 2D product. Sold to hospitals and screening programmes using DBT imaging.

3Vara Workflow
CategoryWorkflow Software
Description

Web-based screening programme platform providing AI-driven case prioritisation, safety net alerts, normal triage, automated reporting, consensus support across centres, and dashboards for operational oversight. Sold as an enterprise subscription to screening programmes.

4Vara Plugin
CategoryWorkflow Software
Description

Lightweight AI deployment solution that integrates directly into existing PACS systems via API, delivering CAD-SR with lesion scores, sub-30-second image analysis, and comprehensive AI reports. Sold to hospitals and radiology practices that prefer PACS-integrated workflows over a separate platform.

5Vara Continuous Monitoring
CategoryClinical Performance Monitoring Service
Description

Subscription monitoring service that tracks AI performance, radiologist-AI interactions, and safety net effectiveness in clinical screening settings, with quarterly review sessions and linkage to cancer registry data. Sold to screening programmes and hospital customers to ensure ongoing clinical safety and accountability.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Major distribution partnership for European market expansion. DeepC distributes Vara AI solutions across European screening programmes.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership through Sectra's integration ecosystem. Sectra Amplifier enables Vara AI to reach more European healthcare customers.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for European market expansion, working alongside other distribution partners to extend Vara's reach.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for European market. Medical Horizons distributes Vara AI solutions to healthcare providers.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborated on PRAIM study - the world's largest prospective AI screening study involving approximately 460,000 women. Published in Nature Medicine.

6Mammography Reference Center North (Oldenburg)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research partnership on interval cancer detection study. Joint authors on peer-reviewed publication in European Journal of Radiology.

vara.ai
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lunit (South Korea) develops AI for mammography (Lunit INSIGHT MMG) and DBT, competing directly with Vara in breast imaging AI with similar workflow integration and radiologist-assist positioning. Both target national screening programmes and offer CE-marked triage tools.

TypeDirect peer
Description

Therapixel (France) offers MammoScreen 2.0, a CE-marked AI for mammography reading assistance, the most direct European competitor to Vara with comparable regulatory positioning, breast imaging focus, and screening programme targeting.

TypeDirect peer
Description

Volpara provides a breast imaging analytics platform (Volpara Scorecard, RiskScore, and Aspen Breast) used by screening programmes and clinics worldwide. It is a direct competitor in breast imaging software, though with more focus on quality/mammography reporting than on AI second reading.

TypeDirect peer
Description

ScreenPoint Medical (Netherlands) offers Transpara, a CE-marked AI decision-support tool for breast imaging (2D and DBT), competing head-to-head with Vara in European screening programmes and offering similar radiologist-assist workflow integration.

TypeDirect peer
Description

iCAD markets ProFound AI for DBT and PowerLook Density Assessment, competing with Vara in breast AI across both 2D and 3D mammography with a US-centric commercial focus and FDA-cleared positioning.

TypeDirect peer
Description

DeepHealth, owned by RadNet, offers Saige-Dx, an FDA-cleared AI for breast cancer detection in DBT, providing a direct competitor in the breast AI second-reader category with a strong US commercial footprint.

TypeBroad incumbent
Description

Hologic is a leading mammography modality vendor (3Dimensions DBT system) and bundles Genius AI detection capabilities with its installed base. As a broad incumbent, it competes with Vara through hardware-software bundling rather than standalone AI sales.

TypeBroad incumbent
Description

Siemens Healthineers offers AI-Rad Companion and broad digital health portfolio including mammography AI. It is a broad incumbent in radiology AI rather than a Vara specialist, with strength via integrated imaging hardware-software suites.

TypeBroad incumbent
Description

GE HealthCare provides the Edison AI platform and breast imaging products, competing with Vara as a broad imaging incumbent with ability to embed AI into its PACS, modalities, and enterprise imaging solutions.

TypeOthers
Description

Sectra provides enterprise PACS and imaging IT across Europe, including the Sectra Amplifier marketplace that distributes Vara AI. It is simultaneously a strategic partner (channel) and a peer in imaging IT, with potential vertical-integration risk over time.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vara

Medical Imaging AI / Radiology AI Softwarevara.ai

Vara is a Berlin-based health AI company that builds CE-marked (Class IIb) independent second-reader software for breast cancer screening, selling enterprise subscriptions to radiologists, hospitals, and national screening programmes across Europe.

What Vara does

Vara (legal entity MX Healthcare GmbH) is a Berlin-based, venture-backed health AI company founded in 2018 that builds clinically validated, CE-marked (Class IIb under EU MDR) artificial intelligence for breast cancer screening. Its core product is an independent second reader for both screening and diagnostic mammography (2D and 3D tomosynthesis), built on a "decision referral" architecture that combines automatic normal triage, a Safety Net for potentially missed findings, and unclassified case handling that defers to radiologist judgment. The platform is offered as a SaaS/enterprise subscription delivered either as a PACS-integrated Vara Plugin or as the web-based Vara Workflow platform for screening programmes, with continuous performance monitoring and quarterly clinical review tied to cancer registry outcomes.

Vara generates revenue through annual, quote-based B2B enterprise subscriptions sold to national screening programmes, hospital radiology departments, and radiology groups. Go-to-market is a hybrid direct enterprise field sales motion (used to land large screening programmes such as Germany's national mammography screening programme, where Vara supports 50–60% of organised screening) combined with distribution partnerships (DeepC, Sectra Amplifier, Quibim, Medical Horizons) that resell the platform across more than 10 European countries. Customer segments are healthcare-provider led — radiologists, screening programmes, policymakers/health authorities, and hospital IT — with regulatory validation, peer-reviewed clinical evidence, and seamless PACS integration positioned as the primary purchase drivers.

The company has built its commercial position around the PRAIM study (approximately 460,000 women, published in Nature Medicine), which underpins regulatory approvals and marketing claims including a 17.6% improvement in cancer detection rate, up to 80% of normal cases pre-reported, an 84% workload reduction in programme-level configuration, and a Safety Net that detected 20.5% of cancers missed by radiologists. Leadership is co-founder led (Jonas Muff, CEO; Stefan Bunk, CTO) with functional depth across regulatory, product, software, sales, partnerships, and finance, and the company is headquartered at the Merantix AI Campus in Berlin.

Vara firmographics

Firmographics
Name
Vara
Legal name
MX Healthcare GmbH
Website
https://vara.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Vara is a Berlin-based health AI company that builds CE-marked (Class IIb) independent second-reader software for breast cancer screening, selling enterprise subscriptions to radiologists, hospitals, and national screening programmes across Europe.
Ownership category
akta.pro rank

Vara industry classification

Industry
Product category
Medical Imaging AI / Radiology AI Software
NAICS
Software Publishers (513210), Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAK
Teleradiology Platforms & Reading Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI mammography screening
  • Breast cancer detection
  • Radiology workflow software
  • Medical imaging AI
  • Clinical decision support

Where Vara is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Vara business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. SaaS/Software Subscription: Cloud-based AI analysis platform deployed via PACS integration or Vara platform. Revenue generated through subscription/licensing model to healthcare systems, screening programmes, and hospitals.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription for healthcare systems and screening programmes

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Vara product offering

Product offering

Core offering

Vara develops and sells a CE-marked Class IIb AI software platform that analyses 2D mammograms and 3D digital breast tomosynthesis images to assist radiologists in breast cancer screening. The platform operates as an independent second reader, combining normal-case triage, a Safety Net that flags potentially missed findings, and automated reporting, and is delivered either as a PACS-integrated plugin or as a web-based workflow platform to hospitals and national/regional screening programmes.

Product overview

Vara offers a unified AI platform for breast cancer screening consisting of the core Vera AI engine and multiple integrated modules. The core Vera AI provides independent second reading capability (CE-marked Class IIb) for both screening and diagnostic mammography. Two deployment options exist: Vera Workflow (web-based platform with AI-driven prioritization, safety net alerts, normal triage, and automated reporting) and Vera Plugin (lightweight PACS-integrated solution with fast image analysis). The product portfolio has expanded from 2D mammography to include Vera Tomosynthesis (DBT) for 3D imaging, with the same CE-marked report and PACS integration. Continuous monitoring services ensure ongoing clinical safety through real-time performance tracking and quarterly review sessions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vara AI (Mammography) CE-marked Class IIb AI platform that analyses 2D mammography images and serves as an independent second reader for both screening and diagnostic mammography, combining normal-case triage, Safety Net alerts, and automated reporting. Sold to hospitals, radiology groups, and national/regional screening programmes.
  • Vara Tomosynthesis (DBT) AI for 3D digital breast tomosynthesis that analyses synthetic 2D, slabs, and complete 3D stacks and delivers the same CE-marked report and PACS integration as the 2D product. Sold to hospitals and screening programmes using DBT imaging.
  • Vara Workflow Web-based screening programme platform providing AI-driven case prioritisation, safety net alerts, normal triage, automated reporting, consensus support across centres, and dashboards for operational oversight. Sold as an enterprise subscription to screening programmes.
  • Vara Plugin Lightweight AI deployment solution that integrates directly into existing PACS systems via API, delivering CAD-SR with lesion scores, sub-30-second image analysis, and comprehensive AI reports. Sold to hospitals and radiology practices that prefer PACS-integrated workflows over a separate platform.
  • Vara Continuous Monitoring Subscription monitoring service that tracks AI performance, radiologist-AI interactions, and safety net effectiveness in clinical screening settings, with quarterly review sessions and linkage to cancer registry data. Sold to screening programmes and hospital customers to ensure ongoing clinical safety and accountability.

Quantifiable outcome

  • Cancer detection rate improved by 17.6% (6.7 vs 5.7 per 1,000)
  • +7 more outcomes

Companies that use Vara

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Vara technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature7 records

Vara partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • DeepCcoreChannel Partner/ Reseller/ DistributorMajor distribution partnership for European market expansion. DeepC distributes Vara AI solutions across European screening programmes.
  • Sectra AmplifiercoreChannel Partner/ Reseller/ DistributorDistribution partnership through Sectra's integration ecosystem. Sectra Amplifier enables Vara AI to reach more European healthcare customers.
  • QuibimcoreChannel Partner/ Reseller/ DistributorDistribution partnership for European market expansion, working alongside other distribution partners to extend Vara's reach.
  • Medical HorizonscoreChannel Partner/ Reseller/ DistributorDistribution partnership for European market. Medical Horizons distributes Vara AI solutions to healthcare providers.
  • University of LübeckmajorStrategic or Co-development PartnerCollaborated on PRAIM study - the world's largest prospective AI screening study involving approximately 460,000 women. Published in Nature Medicine.
  • Mammography Reference Center North (Oldenburg)majorStrategic or Co-development PartnerResearch partnership on interval cancer detection study. Joint authors on peer-reviewed publication in European Journal of Radiology.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Vara competitors and assessment

Company assessment

Direct peers

  • Lunit: Lunit (South Korea) develops AI for mammography (Lunit INSIGHT MMG) and DBT, competing directly with Vara in breast imaging AI with similar workflow integration and radiologist-assist positioning. Both target national screening programmes and offer CE-marked triage tools.
  • Therapixel: Therapixel (France) offers MammoScreen 2.0, a CE-marked AI for mammography reading assistance, the most direct European competitor to Vara with comparable regulatory positioning, breast imaging focus, and screening programme targeting.
  • Volpara Health Technologies: Volpara provides a breast imaging analytics platform (Volpara Scorecard, RiskScore, and Aspen Breast) used by screening programmes and clinics worldwide. It is a direct competitor in breast imaging software, though with more focus on quality/mammography reporting than on AI second reading.
  • ScreenPoint Medical: ScreenPoint Medical (Netherlands) offers Transpara, a CE-marked AI decision-support tool for breast imaging (2D and DBT), competing head-to-head with Vara in European screening programmes and offering similar radiologist-assist workflow integration.
  • iCAD: iCAD markets ProFound AI for DBT and PowerLook Density Assessment, competing with Vara in breast AI across both 2D and 3D mammography with a US-centric commercial focus and FDA-cleared positioning.
  • DeepHealth (RadNet subsidiary): DeepHealth, owned by RadNet, offers Saige-Dx, an FDA-cleared AI for breast cancer detection in DBT, providing a direct competitor in the breast AI second-reader category with a strong US commercial footprint.

Broad incumbents

  • Hologic: Hologic is a leading mammography modality vendor (3Dimensions DBT system) and bundles Genius AI detection capabilities with its installed base. As a broad incumbent, it competes with Vara through hardware-software bundling rather than standalone AI sales.
  • Siemens Healthineers: Siemens Healthineers offers AI-Rad Companion and broad digital health portfolio including mammography AI. It is a broad incumbent in radiology AI rather than a Vara specialist, with strength via integrated imaging hardware-software suites.
  • GE HealthCare: GE HealthCare provides the Edison AI platform and breast imaging products, competing with Vara as a broad imaging incumbent with ability to embed AI into its PACS, modalities, and enterprise imaging solutions.

Others

  • Sectra: Sectra provides enterprise PACS and imaging IT across Europe, including the Sectra Amplifier marketplace that distributes Vara AI. It is simultaneously a strategic partner (channel) and a peer in imaging IT, with potential vertical-integration risk over time.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Vara social profiles

Digital presence

Vara compliance and trust

Trust signal

Compliance2 records

Vara financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vara leadership team

Management profile

Number of profiles

Profiles10 records

Vara funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vara M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vara

What does Vara do?

Vara develops and sells a CE-marked Class IIb AI software platform that analyses 2D mammograms and 3D digital breast tomosynthesis images to assist radiologists in breast cancer screening. The platform operates as an independent second reader, combining normal-case triage, a Safety Net that flags potentially missed findings, and automated reporting, and is delivered either as a PACS-integrated plugin or as a web-based workflow platform to hospitals and national/regional screening programmes.

Is Vara a public or private company?

Vara is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vara founded?

Vara was founded in 2018. It employs 51 to 100 people.

Where is Vara based?

Vara is headquartered in Berlin, Germany, in the Europe region.

How does Vara make money?

One revenue line is on record: saaS/Software Subscription.

Who are Vara's main competitors?

Direct peers on record are Lunit, Therapixel, Volpara Health Technologies, ScreenPoint Medical, iCAD and DeepHealth (RadNet subsidiary). Broad incumbents are Hologic, Siemens Healthineers and GE HealthCare. Sectra is listed as an others.

Does Vara have an API?

No public API is recorded for Vara.

What industry is Vara in?

Vara's product category is Medical Imaging AI / Radiology AI Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 513210 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Analytics InsightFrom AI Diagnosis to Clinical Decisions: Is Healthcare Ready to Trust the Algorithm?A 2025 Nature Medicine study of 463,094 German women found AI-assisted mammography screening detected breast cancer at 6.7 per 1,000 versus 5.7 per 1,000 with standard double reading, with recall rates of 37.4 versus 38.3 per 1,000. The study, funded by AI company Vara, did not establish improved survival or prove AI-led treatment decisions are beneficial.TechRepublicBefore You Paste Anything Into ChatGPT, Check This ListA security checklist advises users against pasting sensitive information into AI chatbots, including passwords, bank details, government IDs, and confidential company data. It categorizes inputs into three groups: paste as-is, edit before pasting, and never paste, with examples like source code and medical records. The guidance notes that AI conversations lack confidentiality protections and may be disclosed to authorities.WebProNewsGermany’s Vara AI Secures World-First Approval to Read Normal Mammograms SoloVara AI received the first global CE mark for autonomous mammogram triage on September 2, 2026, allowing it to declare normal cases without radiologist review. The approval follows a PRAIM study showing AI-supported double reading raised cancer detection to 6.7 per 1,000 versus 5.7 in controls. The system's ATMON monitoring layer ensures safety, with rollout across Europe pending.TechRepublicAI Can Now Clear Some Mammograms Without a Radiologist’s ReviewVara received Class IIb CE certification for its AI system to independently report mammograms as normal, making it the first such breast-screening AI. The system, used since 2019, detected 6.7 cancers per 1,000 women versus 5.7 with standard double reading. The certification sets a precedent for autonomous AI in clinical decisions.The Next WebVara wins world’s first CE mark for AI that clears mammograms aloneVara, a Berlin company, won the world's first CE mark for AI that clears mammograms alone in organized breast screening. The Class IIb certification covers autonomous triage, with ATMON monitoring safety and reverting to radiologist reading if performance drifts. The company expects adoption to follow national guidelines, with no immediate changes.Medical Device NetworkVara nets first CE mark for autonomous AI breast cancer screening toolVara secured a European CE mark for its autonomous AI breast cancer screening triage tool, the first such device globally. The tool, ATMON, was validated in a study of 461,818 women, showing noninferior detection rates. Vara will roll it out to European screening programs and license ATMON independently.GlobeNewswireVara receives CE mark for tomosynthesis AI - extending Europe’s leading screening-grade AI portfolio to 3DVara, a Berlin-based AI company powering over half of Germany\'s organized breast cancer screening program, has received CE class 2b marking under EU MDR for its tomosynthesis (3D mammography) AI solution, extending its screening-grade AI portfolio to 3D imaging. The regulatory approval follows the 2025 publication of the PRAIM study in Nature Medicine, the world\'s largest prospective AI screening study, and comes as European screening programs are at an inflection point driven by new national guidelines and large screening tenders across the continent. Within 12 months of the PRAIM study publication, Vara expanded from Germany to over 10 European countries and signed major distribution partnerships.PR NewswireAtlas AI Labs bringt den ersten genehmigungsfreien, durch Vermögenswerte gedeckten Token aus Dubai auf den MarktAtlas AI Labs FZE, a Dubai-registered subsidiary of US fintech company Atlas Capital Team Inc., has received initial permit approval (IPA) from Dubai's Virtual Assets Regulatory Authority (VARA) to launch the USAF+ token—the first asset-backed virtual asset available in a fully permissionless environment.PR NewswirePyse and MANTRA Finance Receive VARA NOC to Launch Shariah Compliant RWA backed by Dubai's Food delivery EVsPyse has received a Non-Objection Certificate (NOC) from Dubai's Virtual Assets Regulatory Authority (VARA) to launch PYSE Green Velocity 1, a Shariah-compliant token that fractionalizes lease-based cash flows from electric motorcycles deployed across Dubai's last mile delivery ecosystem. The product, distributed through MANTRA Finance as a VARA-licensed broker-dealer, is scheduled to launch on February 10, 2026, following nearly a year of collaboration with Shariah advisor AmanX. This approval marks one of the first regulated, Shariah-compliant real-world asset tokenizations in Dubai, representing a step toward bringing income-generating infrastructure assets into regulated virtual asset markets.Digital JournalAI agent pioneer sparks new momentum in healthcare transformationAn AI agent intervened in urgent healthcare processes at a Phoenix clinic, significantly speeding up prior authorization for a critical asthma drug. The technology, driven by Vara Imandi, utilizes AI to automate administrative tasks, reducing approval timelines by up to 70% while improving efficiency in healthcare systems. As this technology transforms care delivery globally, its ethical implications remain a topic of discussion.